Bristol-Myers Squibb Co. (BMY) Misses Q2 EPS by 1c
Bristol-Myers Squibb Co. (NYSE: BMY) reported Q2 EPS of $0.44, $0.01 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $4.05 billion versus the consensus estimate of $4.07 billion.
Bristol-Myers Squibb Co. sees FY2013 EPS of $1.70-$1.78, versus the consensus of $1.79.
“In the second quarter, the strength in the performance of some of our key products, the important data we presented across our portfolio and the key regulatory filings we made in the U.S. strengthen our confidence as we build a solid foundation for future growth,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “We will continue to invest the necessary resources across our portfolio to grow existing brands, support the execution of new launches and deliver a diverse and sustainable pipeline,” Andreotti said.
For earnings history and earnings-related data on Bristol-Myers Squibb Co. (BMY) click here.
Bristol-Myers Squibb Co. sees FY2013 EPS of $1.70-$1.78, versus the consensus of $1.79.
“In the second quarter, the strength in the performance of some of our key products, the important data we presented across our portfolio and the key regulatory filings we made in the U.S. strengthen our confidence as we build a solid foundation for future growth,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “We will continue to invest the necessary resources across our portfolio to grow existing brands, support the execution of new launches and deliver a diverse and sustainable pipeline,” Andreotti said.
For earnings history and earnings-related data on Bristol-Myers Squibb Co. (BMY) click here.